1. Pink Sheet
  2. >>Product Reviews

Perrigo's OTC Priority Shows In Launch Of Imodium Multi-Symptom Equivalent

 
• By Eileen Francis

Perrigo is launching generic of J&J’s OTC Imodium Multi-Symptom Relief product for diarrhea and gas. An analyst estimates the product could generate $15m in annualized sales.

Perrigo Co. PLC's generic equivalent of Johnson & Johnson’s OTC Imodium Multi-Symptom Relief – recently approved by FDA for symptoms of diarrhea plus bloating, pressure and cramps – soon will be available in US stores.

Containing loperamide hydrochloride 2 mg for control and relief of diarrhea and simethicone 125 mg to relieve pain associated with gas, the formula will be marketed as a store...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews

US FDA Meeting Drought Ends … With A Vengeance

 
• By Michael McCaughan

The first 100 days of the Trump Administration were notable for an extraordinary decline in the number of public meetings hosted by the US Food and Drug Administration. But the schedule changed quickly.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

HHS Rescinds COVID-19 Vaccine Advice, Usurping US CDC Role

 
• By Sue Sutter

By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.